STOCK TITAN

Adamis Pharmaceuticals Corporation - $ADMP STOCK NEWS

Welcome to our dedicated page for Adamis Pharmaceuticals Corporation news (Ticker: $ADMP), a resource for investors and traders seeking the latest updates and insights on Adamis Pharmaceuticals Corporation stock.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a renowned specialty biopharmaceutical company committed to developing and commercializing therapeutic solutions in critical areas such as opioid overdose, allergies, respiratory diseases, and inflammatory conditions. The company operates in two primary divisions: specialty pharmaceuticals and biotechnology.

In the specialty pharmaceutical division, Adamis has a promising pipeline that includes four pivotal products: the Epinephrine Injection Pre-Filled Syringe (PFS) for emergency treatment of anaphylaxis, APC-1000 and APC-5000 (dry powder inhalers) for asthma and COPD, and APC-3000, a Hydrofluoroalkane (HFA) inhaled nasal steroid for treating allergic rhinitis. Their strategy aims to offer cost-effective therapeutic alternatives for large market needs, ensuring affordability and accessibility. The company follows the 505(b)(2) regulatory pathway to streamline development and reduce time to market.

In the biotechnology division, Adamis focuses on innovative treatments for diseases with considerable unmet needs. This division's portfolio includes four developmental products, such as TeloB-Vax, which holds promise for treating cancer and infectious diseases. Following its recent merger with DMK Pharmaceuticals, Adamis is now advancing DPI-125, a clinical-stage therapeutic aimed at treating opioid use disorder, a significant public health crisis that requires urgent intervention.

Adamis has received FDA approval for two critical products: ZIMHI® (naloxone) Injection for opioid overdose and SYMJEPI® (epinephrine) Injection for acute allergic reactions, including anaphylaxis. These products are designed to provide rapid, life-saving interventions in emergency situations.

Financially, Adamis is navigating challenges, including maintaining Nasdaq listing compliance and achieving financial stability. Recent measures include a reverse stock split to meet Nasdaq requirements and securing additional funding through public offerings.

Adamis is actively involved in partnerships and collaborations to further its mission. The company recently participated in the White House Roundtable on Opioid Reversal Product Manufacturers and received a grant from the NIH to develop treatment for alcohol use disorder. These initiatives underline Adamis' commitment to addressing public health crises through innovative therapeutic solutions.

The management team, led by CEO Ebrahim Versi, MD, PhD, is focused on expanding the company's product portfolio and improving financial health. The recent merger with DMK Pharmaceuticals is a strategic move to enhance their capabilities in developing neuro-based treatments and leveraging DMK's extensive library of small molecule neuropeptide analogues.

Adamis Pharmaceuticals remains dedicated to making a significant impact in the biopharmaceutical landscape by developing and commercializing treatments that address critical health challenges, ensuring better outcomes for patients worldwide.

Rhea-AI Summary
Adamis Pharmaceuticals Corporation changes its name to DMK Pharmaceuticals Corporation and will begin trading under the ticker symbol 'DMK' on September 8, 2023. The company's new strategic focus is on advancing small molecules for the treatment of substance use disorders. DPI-125, the company's lead clinical stage compound, is expected to have several significant milestones by the end of 2024. These include a transdermal delivery system, safety study results compared to fentanyl, pharmacokinetic study results in humans, and abuse liability study results compared to current treatments for OUD and pain relief.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none
-
Rhea-AI Summary
Adamis Pharmaceuticals Corporation announces Q2 2023 financial results and recent corporate developments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Adamis Pharmaceuticals Corporation has closed its public offering of 5,930,000 units, each consisting of one share of common stock and one warrant. The units were sold at a public offering price of $1.35 per unit, resulting in gross proceeds of approximately $8.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.18%
Tags
Rhea-AI Summary
Adamis Pharmaceuticals Corporation announces pricing of public offering at $1.35 per unit, expected to raise approximately $8.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-66.67%
Tags
-
Rhea-AI Summary
Adamis Pharmaceuticals commits to funding an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit. The funding will support the work of Dr. Albert Dahan, an expert on opioid-induced respiratory depression. The collaboration aims to assess the efficacy of 5mg intramuscular ZIMHI versus 4mg intranasal naloxone in reversing fentanyl-induced respiratory depression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.58%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.27%
Tags
none
Rhea-AI Summary
Adamis Pharmaceuticals CEO participates in White House Roundtable on Opioid Crisis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.32%
Tags
none
-
Rhea-AI Summary
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has announced the completion of its merger with DMK Pharmaceuticals Corporation. The combined company will focus on increasing sales of Adamis' commercial products and advancing DMK's lead clinical stage compound, DPI-125, for the treatment of opioid use disorder (OUD). Ebrahim Versi, CEO of DMK, has been named CEO of Adamis and Chairman of the Board of Directors. The global opioid market in 2021 was reported to be greater than $22 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.2%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.57%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What are the main therapeutic areas Adamis Pharmaceuticals Corporation focuses on?

Adamis Pharmaceuticals focuses on opioid overdose, allergies, respiratory diseases, and inflammatory conditions.

What products are in Adamis Pharmaceuticals' pipeline?

Adamis' pipeline includes the Epinephrine Injection Pre-Filled Syringe for anaphylaxis, APC-1000 and APC-5000 inhalers for asthma and COPD, and APC-3000 for allergic rhinitis.

What recent merger has Adamis Pharmaceuticals completed?

Adamis recently merged with DMK Pharmaceuticals, enhancing their capabilities in developing treatments for opioid use disorder and other neuro-based conditions.

What are Adamis' FDA-approved products?

Adamis has FDA-approved ZIMHI® (naloxone) Injection for opioid overdose and SYMJEPI® (epinephrine) Injection for acute allergic reactions.

What steps has Adamis taken to maintain its Nasdaq listing?

Adamis has implemented a reverse stock split to meet the $1.00 minimum bid price requirement and continues to pursue strategic actions to regain compliance.

Who is the CEO of Adamis Pharmaceuticals?

Ebrahim Versi, MD, PhD, is the current CEO of Adamis Pharmaceuticals.

What was the outcome of Adamis' participation in the White House Roundtable?

Adamis participated in discussions to increase access to naloxone for opioid overdose treatment and is working with federal agencies to support public-private partnerships.

What financial strategies has Adamis employed recently?

Adamis has conducted public offerings to secure funding and has worked on mergers and grants to support its research and development efforts.

What is the objective of Adamis' grant from the NIH?

The NIH grant supports the development of a novel bifunctional small molecule for the treatment of alcohol use disorder.

How does Adamis plan to enhance its product portfolio?

Adamis plans to develop DPI-125 for opioid use disorder and expand into treatments for moderate to severe pain, bladder control problems, and Parkinson's disease.

Adamis Pharmaceuticals Corporation

Nasdaq:ADMP

ADMP Rankings

ADMP Stock Data

7.25M
9.14M
7.81%
16.59%
1.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About ADMP

adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a